Long-term impact of androgen-deprivation therapy on physical function and quality of life

被引:46
|
作者
Alibhai, Shabbir M. H. [1 ,2 ,3 ]
Breunis, Henriette [1 ]
Timilshina, Narhari [1 ]
Naglie, Gary [2 ,3 ,4 ]
Tannock, Ian [1 ,2 ]
Krahn, Murray [1 ,2 ,3 ]
Warde, Padraig [5 ]
Fleshner, Neil E. [6 ]
Canning, Sarah Duff [7 ]
Tomlinson, George [1 ,2 ,3 ,8 ]
机构
[1] Univ Hlth Network, Dept Med, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[4] Baycrest Ctr Geriatr Care, Toronto, ON, Canada
[5] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada
[6] Univ Toronto, Dept Surg, Toronto, ON, Canada
[7] Univ Hlth Network, Dept Neurosci, Toronto, ON M5G 2C4, Canada
[8] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada
关键词
activities of daily living; androgen-deprivation therapy; physical function; prospective study; prostate carcinoma; quality of life; PROSTATE-CANCER; PHYSIOLOGICAL-ASPECTS; HANDGRIP STRENGTH; DECISION-MAKING; HEALTH; MEN; MANAGEMENT; MORTALITY; AGE;
D O I
10.1002/cncr.29355
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUNDThis study examined the impact of androgen-deprivation therapy (ADT) on physical function and quality of life (QOL) over 36 months. METHODSEighty-seven men with nonmetastatic prostate cancer (PC) who were starting continuous ADT and 2 control groups (86 PC controls without ADT and 86 healthy controls), matched by age and education, were enrolled. Physical function was assessed with the 6-minute walk test (6MWT), grip strength, and Timed Up and Go (TUG) test. QOL was measured with the 36-Item Short Form Health Survey of the Medical Outcomes Study. Subjects were assessed at the baseline and at 3, 6, 12, 18, 24, 30, and 36 months. Mixed effects regression models were fitted with adjustments for baseline covariates. RESULTSThe 6MWT distance improved initially and then stabilized in both control groups but remained unchanged for ADT users (P=.0030). Grip strength remained stable in control groups but declined sharply in the ADT group by 3 months and then remained stable to 36 months (P=.0041). TUG scores declined gradually in the ADT group over 36 months but were unchanged in control groups (P=.0008). Aggregate physical QOL declined in ADT users over time but remained stable in control groups (P=.0001). Aggregate mental QOL was stable in all groups. Declines seen in the first year of ADT use generally persisted over 36 months and were independent of age. CONCLUSIONSPreviously noted physical side effects over the first 12 months of ADT persisted or continued to worsen over an additional 2 years with no evidence of recovery. Exercise interventions to counteract these declines may be warranted. Cancer 2015;121:2350-2357. (c) 2015 American Cancer Society. In men with nonmetastatic prostate cancer, androgen-deprivation therapy is associated with declines in physical function (endurance, upper extremity strength, and lower extremity function) and quality of life over 1 year that persist or decline with 2 additional years of use.
引用
收藏
页码:2350 / 2357
页数:8
相关论文
共 50 条
  • [1] Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy
    C Sevilla
    S L Maliski
    L Kwan
    S E Connor
    M S Litwin
    [J]. Prostate Cancer and Prostatic Diseases, 2012, 15 : 237 - 243
  • [2] Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy
    Sevilla, C.
    Maliski, S. L.
    Kwan, L.
    Connor, S. E.
    Litwin, M. S.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (03) : 237 - 243
  • [3] Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer
    Alibhai, Shabbir M. H.
    Breunis, Henriette
    Timilshina, Narhari
    Johnston, Calvin
    Tomlinson, George
    Tannock, Ian
    Krahn, Murray
    Fleshner, Neil E.
    Warde, Padraig
    Canning, Sarah Duff
    Klotz, Lawrence
    Naglie, Gary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) : 5038 - 5045
  • [4] Impact of 36 months of androgen-deprivation therapy (ADT) on physical function and quality of life (QOL) in men with nonmetastatic prostate cancer
    Alibhai, Shabbir M. H.
    Breunis, Henriette
    Timilshina, Narhari
    Tomlinson, George A.
    Canning, Sarah Duff
    Fleshner, Neil Eric
    Krahn, Murray
    Tannock, Ian
    Warde, Padraig Richard
    Naglie, Gary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [5] Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy
    Braga-Basaria, Milena
    Dobs, Adrian S.
    Muller, Denis C.
    Carducci, Michael A.
    John, Majnu
    Egan, Josephine
    Basaria, Shehzad
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3979 - 3983
  • [6] Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate Cancer
    Kohutek, Zachary A.
    Weg, Emily S.
    Pei, Xin
    Shi, Weiji
    Zhang, Zhigang
    Kollmeier, Marisa A.
    Zelefsky, Michael J.
    [J]. UROLOGY, 2016, 87 : 146 - 152
  • [7] Long-term Impact of Androgen-deprivation Therapy on Cardiovascular Morbidity After Radiotherapy for Clinically Localized Prostate Cancer EDITORIAL COMMENT
    Nguyen, Paul L.
    [J]. UROLOGY, 2016, 87 : 152 - 152
  • [8] Predictors of physical activity and quality of life in New Zealand prostate cancer survivors undergoing androgen-deprivation therapy
    Keogh, Justin W. L.
    Shepherd, Daniel
    Krageloh, Christian U.
    Ryan, Clare
    Masters, Jonathan
    Shepherd, Greg
    MacLeod, Rod
    [J]. NEW ZEALAND MEDICAL JOURNAL, 2010, 123 (1325) : 20 - 29
  • [9] Biopsychosocial impact of prostate cancer and androgen-deprivation therapy
    Tripp, Dean A.
    Verreault, Phylicia
    Tong, Steven
    Izard, Jason
    Black, Angela
    Siemens, D. Robert
    [J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (10): : 338 - 343
  • [10] Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer
    Chi Nguyen
    Lairson, David R.
    Swartz, Michael D.
    Du, Xianglin L.
    [J]. PHARMACOTHERAPY, 2018, 38 (10): : 999 - 1009